Effect of a nutritional supplementation on bone health in Chilean elderly subjects with femoral osteoporosis.
OBJECTIVE
To study the effects of a special nutritional supplement on bone mineral density and bone turnover markers in Chilean elderly subjects with femoral osteoporosis.


METHODS
Public primary health care clinics in Chile.


METHODS
Free living elderly subjects with femoral osteoporosis.


METHODS
Subjects were randomized to receive the usual nutritional supplement provided by the Chilean Ministry of Health or a special nutritional supplement providing, among other nutrients, 90 mg isoflavones, 800 mg calcium, 400 IU vitamin D, 60 ug vitamin K and 31 g proteins per day.


METHODS
At baseline, and after six and twelve months of supplementation, body composition, bone mineral density, serum 25 OH vitamin D, intact parathyroid hormone (iPTH), osteocalcin, decarboxylated osteocalcin, urinary aminoterminal telopeptide of type I collagen (NTX), deoxypyridoline cross links (Dpd) and equol were measured. Every month, urinary daidzein was measured in a morning urine sample.


RESULTS
No differences between treatment groups were observed in body composition or bone mineral density changes. The group receiving the special supplement had a significant increase in serum 25 OH vitamin D and a significant decrease in serum iPTH and decarboxylated osteocalcin. No association between daidzein or equol excretion and changes in bone mineralization was observed.


CONCLUSIONS
A special supplement delivered to elderly subjects with osteoporosis improved serum vitamin D and reduced serum iPTH and undercarboxylated osteocalcin levels but did not affect BMD.
Bunout
Daniel
D
INTA, Department of Medicine, Central Campus Facultyof Medicine, University of Chile, Santiago, CHILE. dbunout@inta.cl
Barrera
Gladys
G
Leiva
Laura
L
Gattas
Vivien
V
de la Maza
María Pía
MP
Haschke
Ferdinand
F
Steenhout
Philippe
P
Klassen
Petra
P
Hager
Corinne
C
Offord
Elizabeth
E
Hirsch
Sandra
S
D000368:Aged; D000704:Analysis of Variance; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism / Q000627:therapeutic use; D002677:Chile; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000097:blood; D011446:Prospective Studies; D016896:Treatment Outcome; D014807:Vitamin D / Q000378:metabolism / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D007529:Isoflavones; D010281:Parathyroid Hormone; D015675:Osteocalcin; D014807:Vitamin D; D002118:Calcium